Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312857501> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W4312857501 abstract "We attempt to study the efficacy and adverse reactions of carboplatin, nab-paclitaxel regimen combined with atezolizumab in non-small cell lung cancer treatment. We randomly selected 120 non-small cell lung cancer patients who received therapy in our hospital from January 2019 to December 2021 and divided them into two groups, 60 cases respectively. Treated control group with carboplatin and paclitaxel combined with pembrolizumab, while observation group with carboplatin and albumin paclitaxel combined with pembrolizumab. Compared both groups on the efficacy, incidence of adverse reactions, levels of peripheral blood lymphocyte subsets and serum tumor markers. After treatment, observation group possessed higher objective remission rate and disease control rate than control group (p<0.05); observation group had lower adverse reactions rate during the treatment period than control group (p<0.05); observation group had higher cluster of differentiation 3+, cluster of differentiation 4+ and cluster of differentiation 4+/cluster of differentiation 8+ values than control group, but it possessed lower cluster of differentiation 8+ values than control group (p<0.05). Observation group had lower cytokeratin 19 fragment antigen 21-l, squamous cell carcinoma antigen, carbohydrate antigen 125 and carcinoembryonic antigen levels than control group (p<0.05). Carboplatin, nab-paclitaxel regimen combined with atezolizumab in treating non-small cell lung cancer patients can effectively alleviate and control their disease, reduce the risk of adverse reactions during the treatment process and improve the body’s immune function, which is worthy of promotion." @default.
- W4312857501 created "2023-01-05" @default.
- W4312857501 creator A5000771815 @default.
- W4312857501 creator A5012041701 @default.
- W4312857501 creator A5027475930 @default.
- W4312857501 creator A5029582203 @default.
- W4312857501 date "2022-01-01" @default.
- W4312857501 modified "2023-10-14" @default.
- W4312857501 title "Efficacy and Adverse Reactions of Carboplatin, Nab-Paclitaxel Regimen Combined with Atezolizumab in the Treatment of Non-Small Cell Lung Cancer" @default.
- W4312857501 doi "https://doi.org/10.36468/pharmaceutical-sciences.spl.525" @default.
- W4312857501 hasPublicationYear "2022" @default.
- W4312857501 type Work @default.
- W4312857501 citedByCount "0" @default.
- W4312857501 crossrefType "journal-article" @default.
- W4312857501 hasAuthorship W4312857501A5000771815 @default.
- W4312857501 hasAuthorship W4312857501A5012041701 @default.
- W4312857501 hasAuthorship W4312857501A5027475930 @default.
- W4312857501 hasAuthorship W4312857501A5029582203 @default.
- W4312857501 hasBestOaLocation W43128575011 @default.
- W4312857501 hasConcept C121608353 @default.
- W4312857501 hasConcept C126322002 @default.
- W4312857501 hasConcept C143998085 @default.
- W4312857501 hasConcept C197934379 @default.
- W4312857501 hasConcept C203014093 @default.
- W4312857501 hasConcept C2775949291 @default.
- W4312857501 hasConcept C2776256026 @default.
- W4312857501 hasConcept C2776694085 @default.
- W4312857501 hasConcept C2777292972 @default.
- W4312857501 hasConcept C2777387746 @default.
- W4312857501 hasConcept C2777701055 @default.
- W4312857501 hasConcept C2778239845 @default.
- W4312857501 hasConcept C2780057760 @default.
- W4312857501 hasConcept C2781413609 @default.
- W4312857501 hasConcept C2781451048 @default.
- W4312857501 hasConcept C71924100 @default.
- W4312857501 hasConcept C90924648 @default.
- W4312857501 hasConceptScore W4312857501C121608353 @default.
- W4312857501 hasConceptScore W4312857501C126322002 @default.
- W4312857501 hasConceptScore W4312857501C143998085 @default.
- W4312857501 hasConceptScore W4312857501C197934379 @default.
- W4312857501 hasConceptScore W4312857501C203014093 @default.
- W4312857501 hasConceptScore W4312857501C2775949291 @default.
- W4312857501 hasConceptScore W4312857501C2776256026 @default.
- W4312857501 hasConceptScore W4312857501C2776694085 @default.
- W4312857501 hasConceptScore W4312857501C2777292972 @default.
- W4312857501 hasConceptScore W4312857501C2777387746 @default.
- W4312857501 hasConceptScore W4312857501C2777701055 @default.
- W4312857501 hasConceptScore W4312857501C2778239845 @default.
- W4312857501 hasConceptScore W4312857501C2780057760 @default.
- W4312857501 hasConceptScore W4312857501C2781413609 @default.
- W4312857501 hasConceptScore W4312857501C2781451048 @default.
- W4312857501 hasConceptScore W4312857501C71924100 @default.
- W4312857501 hasConceptScore W4312857501C90924648 @default.
- W4312857501 hasIssue "S4" @default.
- W4312857501 hasLocation W43128575011 @default.
- W4312857501 hasOpenAccess W4312857501 @default.
- W4312857501 hasPrimaryLocation W43128575011 @default.
- W4312857501 hasRelatedWork W2012171803 @default.
- W4312857501 hasRelatedWork W2053778437 @default.
- W4312857501 hasRelatedWork W2153557259 @default.
- W4312857501 hasRelatedWork W2289428780 @default.
- W4312857501 hasRelatedWork W2888392413 @default.
- W4312857501 hasRelatedWork W2948776902 @default.
- W4312857501 hasRelatedWork W2948845624 @default.
- W4312857501 hasRelatedWork W3118834521 @default.
- W4312857501 hasRelatedWork W4238509468 @default.
- W4312857501 hasRelatedWork W4244943686 @default.
- W4312857501 hasVolume "84" @default.
- W4312857501 isParatext "false" @default.
- W4312857501 isRetracted "false" @default.
- W4312857501 workType "article" @default.